Lv3
322 积分 2025-06-29 加入
Shengbai oral solution for chemotherapy-induced neutropenia and symptom management in non-small cell lung cancer: A multicenter, randomized, open-label trial
9小时前
已完结
Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia
7天前
已关闭
Impacts of early therapy response, interval to therapy interruption, and cumulative therapy interruption duration on outcome of ibrutinib therapy in relapsed/refractory chronic lymphocytic leukemia
11天前
已完结
Deuterated water labeling in ibrutinib-treated patients with CLL: leukemia cell kinetics correlate with IGHV, ZAP-70, and MRD
11天前
已关闭
Impacts of early therapy response, interval to therapy interruption, and cumulative therapy interruption duration on outcome of ibrutinib therapy in relapsed/refractory chronic lymphocytic leukemia
11天前
已完结
Real-World Treatment Patterns, Adverse Events, Resource Use, and Costs Among Commercially Insured, Younger Patients with Chronic Lymphocytic Leukemia in the USA: A Retrospective Cohort Study
11天前
已完结
Survival trends in chronic lymphocytic leukemia across treatment eras: US SEER database analysis (1985-2017)
11天前
已完结
Use of Ibrutinib in 10 Patients with Treatment-Naïve or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in Real-World Clinical Practice -A Report from a Single Medical Institution
11天前
已完结
Ibrutinib in Advanced Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Lower Risk of Hepatitis B Virus Reactivation
11天前
已完结
Ibrutinib in relapsed/refractory patients with Waldenström macroglobulinemia: a real-life, retrospective study on behalf of the "RTL" (regional Tuscan lymphoma network)
11天前
已完结
皖公网安备34019202002308
